Key result
Cilostazol reduced plasma triglycerides and increased HDL cholesterol, improving the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes.
Why the study?
Does cilostazol improve the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes?
Does cilostazol improve the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes?
Cilostazol improves surrogate lipid markers like triglycerides and HDL in patients with PAD or diabetes, though its clinical impact on atherogenic dyslipidemia remains to be established.
Answers are grounded in this paper and cite their sources.
Supports surrogate lipid benefits with cilostazol in PAD or diabetes; leaves open effects on clinical outcomes.
Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprotein (HDL) cholesterol concentrations. Additional effects on pro-atherogenic lipoproteins and apolipoproteins include those on remnant-like particles, HDL subclasses, apolipoprotein B and postprandial lipemia. Cilostazol can improve the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes. Further studies are needed to establish whether cilostazol treatment exerts clinically relevant effects on atherogenic dyslipidemia in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Rizzo et al. (2011) studied this question. Cilostazol reduced plasma triglycerides and increased HDL cholesterol, improving the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: